期刊文献+

血清脂蛋白相关磷脂酶A2与急性冠脉综合征危险分层的相关性研究 被引量:4

Correlation Study of Serum Lipoprotein Associated Phospholipase A2 and Risk Stratification of Acute Coronary Syndrome
下载PDF
导出
摘要 目的探讨血清脂蛋白相关磷脂酶A2(Lp-PLA2)与急性冠脉综合征(ACS)危险分层GRACE积分之间的相关性。方法选择2012年11月至2016年6月我科住院确诊ACS患者203例,患者根据GRACE积分被分为低危组(83例)、中危组(31例)、高危组(124例),并检测血清Lp-PLA2水平,分析血清Lp-PLA2水平与危险分层GRACE积分之间的关系。结果血清Lp-PLA2水平在低危组为(171.31±58.31)ng/mL、中危组为(258.42±78.94)ng/mL、高危组为(309.84±91.73)ng/mL,三组比较差异有统计学意义(P<0.05);线性回归分析提示ACS患者血清Lp-PLA2水平与GRACE积分呈正相关(r=0.791,P<0.01)。结论血清Lp-PLA2水平对于早期评价ACS患者风险程度具有一定的临床意义。 Objective To investigate the correlation between serum lipoprotein associated phospholipase A2( Lp-PLA2)and GRACE scoring,risk stratification of acute coronary syndrome( ACS). Methods 203 cases of confirmed ACS patients hospitalized between November 2012 and June 2016 in our department were included and divided into low-risk group( 83 cases),medium-risk group( 31 cases) and high-risk group( 124 cases) according to GRACE scoring. Serum Lp-PLA2 level was determined and relationship between serum Lp-PLA2 level and GRACE scoring was analyzed. Results Serum Lp-PLA2 level in low-risk group was( 171. 31 ± 58. 31) ng/mL,in medium-risk group was( 258. 42 ±78. 94) ng/mL and in high-risk group was( 309. 84 ± 91. 73)ng/mL. Comparing the Lp-PLA2 level of the three groups,there were statistically significant differencesamong the three groups( P〈0. 05). Linear regression analysis indicated a positive correlation between serum Lp-PLA2 level and GRACE scoring in ACS patients( r = 0. 791,P〈0. 01). Conclusion Serum Lp-PLA2 level has certain clinical significance for the early evaluation of risk degree of ACS patients.
作者 艾民 颜昌福 夏福纯 周双陆 贺剑 李翠萍 Ai Min Yah Changfu Xia Fuchun et al(General Hospital of Panzhihua Iron and Steel Group, Panzhihua, Sichuan 617023, China)
出处 《四川医学》 CAS 2017年第4期373-375,共3页 Sichuan Medical Journal
基金 四川省卫生和计划生育委员会科研课题(编号:150097)
关键词 急性冠脉综合征 危险分层 全球急性冠状动脉事件注册评分 脂蛋白相关磷脂酶A2 acute coronary syndrome risk stratification global acute coronary events registry score lipoprotein associated phospholipase A2
  • 相关文献

参考文献3

二级参考文献40

  • 1郝恒剑,李耘,李康,魏嘉平,汪家瑞.急性下壁心肌梗死合并完全性房室阻滞患者冠状动脉病变的特点及临床预后[J].中国循环杂志,2004,19(4):255-257. 被引量:2
  • 2曹雅旻,胡大一,闫丽.急性冠状动脉综合征严重程度与血浆氨基酸N末端脑钠肽原浓度相关性的研究[J].中华心血管病杂志,2005,33(10):899-902. 被引量:60
  • 3洪衡,王明生,王河,李明昌,王磊,肖毅,杨光,王红梅,任海明,贾宁,谭丽玲,顼志敏.不同类型急性心肌梗死冠状动脉病变特点的观察[J].中国循环杂志,2007,22(3):187-190. 被引量:11
  • 4Zalewski A, Macphee C. Role of lipoprotein-associated phospholipase A2 in atherosclerosis biology, epidemiology, and possible therapeutic target. Arterioscler Thromb Vasc Biol 2005; 25: 923-931.
  • 5Waxman S, Ishibashi F, Muller JE. Detection and treatment of vulnerable plaques and vulnerable patients: novel approaches to prevention of coronary events. Circulation 2006; 114: 2390-2411.
  • 6Kolodgie FD, Burke AP, Skorija KS, Ladich E, Kutys R, Makuria AT, et al. Lipoprotein-associated phospholipase A2 protein expression in the natural progression of human coronary atherosclerosis. Arterioscler Thromb Vase Biol 2006; 26: 2523-2529.
  • 7Wilensky RL, Shi Y, Mohler ER 3rd, Hamamdzic D, Burgert ME, Li J, et al. Inhibition of lipoprotein-associated phospholipase A2 reduces complex coronary atherosclerotic plaque development. Nat Med 2008; 14: 1059-1066.
  • 8Corson MA, Jones PH, Davidson MH. Review of the evidence for the clinical utility of lipoprotein-associated phospholipase A2 as a cardiovascular risk marker. Am J Cardiol 2008; 101 (12A): 41F-50E.
  • 9Koenig W, Khuseyinova N. Lipoprotein-associated and secretory phospholipase A2 in cardiovascular disease: the epidemiological evidence. Cardiovasc Drugs Ther 2009; 23: 85-92.
  • 10Anderson JL. Lipoprotein-associated phospholipase A2: an independent predictor of coronary artery disease events in primary and secondary prevention. Am J Cardiol 2008; 101 (12A): 23F-33E.

共引文献64

同被引文献27

引证文献4

二级引证文献12

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部